+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Pancreatic Cancer Drugs Market 2020-2026

  • PDF Icon


  • May 2020
  • Region: Global
  • Orion Market Research Private Limited
  • ID: 5129772
UP TO OFF until Dec 31st 2022
Global Pancreatic Cancer Drugs Market Size, Share & Trends Analysis Report, By Cancer Type (Exocrine and Endocrine), By Treatment Type (Chemotherapy Drugs, Targeted Therapy Drugs, and Immunotherapy Drugs) and Forecast, 2020-2026
The global pancreatic cancer drugs market is estimated to grow significantly during the forecast period. Rising prevalence of pancreatic cancer and significant geriatric population base are primarily contributing to market growth. As per the United Nations, in 2019, 703 million people were aged 65 and over globally. By 2050, the number of older persons is anticipated to double to 1.5 billion. The percentage of the population aged 65 years and over increased from 6% in 1990 to 9% in 2019. Pancreatic adenocarcinoma primarily occurs after aged over 60 years. Therefore, the rising ageing population will eventually result in the increasing incidences of pancreatic adenocarcinoma. The management of pancreatic cancer in the geriatric population is gaining significance, which in turn, is contributing to the demand for chemotherapy, immunotherapy and targeted therapy in which drugs are used for the treatment of the condition. Some immunotherapy and targeted therapy drugs are under trials for the treatment of pancreatic cancer, which is offering an opportunity for the growth of the market.

Geographically, the global pancreatic cancer drugs market is segmented into four major regions, including North America, Europe, Asia-Pacific, and Rest of the World (RoW). In 2019, North America is anticipated to hold a significant share in the market owing to the significant rise in the incidences of pancreatic cancer and the potential availability of cancer treatment in the region. Asia-Pacific is estimated to witness considerable share in the market owing to the significant geriatric population base and rising incidences of pancreatic cancer in the region. As per the World Health Organization (WHO), in 2018, the number of new incidences of pancreas cancer was 116,291 in China, ranked 9th among all new cancer incidences in the country. This will contribute to the emerging demand for pancreatic cancer treatment in the country.

Some crucial players in the market include Eli Lilly and Co., F- Hoffman La-Roche AG, Novartis International AG, Boehringer Ingelheim GmbH, and Merck & Co., Inc. Mergers and acquisitions, product launches, and partnerships and collaborations are considered as crucial strategies adopted by the market players. For instance, in December 2019, AstraZeneca and Merck & Co., Inc. declared the US FDA approval of Lynparza (olaparib) for the maintenance treatment of patients with metastatic pancreatic adenocarcinoma. This is intended for those patients whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy treatment.

Research Methodology

The market study of the global pancreatic cancer drugs market is incorporated by extensive primary and secondary research. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.

In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity in the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation:

1. Global Pancreatic Cancer Drugs Market Research and Analysis by Cancer Type
2. Global Pancreatic Cancer Drugs Market Research and Analysis by Treatment Type

The Report Covers
  • Comprehensive research methodology of the global pancreatic cancer drugs market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global pancreatic cancer drugs market.
  • Insights about market determinants, which are stimulating the global pancreatic cancer drugs market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
1.2.3. By Stakeholders
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Pipeline Analysis
2.4. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Eli Lilly and Co. Overview Financial Analysis SWOT Analysis Recent Developments
3.3.2. F. Hoffmann-La Roche AG Overview Financial Analysis SWOT Analysis Recent Developments
3.3.3. Novartis International AG Overview Financial Analysis SWOT Analysis Recent Developments
3.3.4. Boehringer Ingelheim GmbH Overview Financial Analysis SWOT Analysis Recent Developments
3.3.5. Merck & Co., Inc. Overview Financial Analysis SWOT Analysis Recent Developments
4. Market Determinants
4.1 Motivators
4.2 Restraints
4.3 Opportunities
5. Market Segmentation
5.1. Global Pancreatic Cancer Drugs Market by Cancer Type
5.1.1. Exocrine
5.1.2. Endocrine
5.2. Global Pancreatic Cancer Drugs Market by Treatment Type
5.2.1. Chemotherapy Drugs
5.2.2. Targeted Therapy Drugs
5.2.3. Immunotherapy Drugs
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. AbbVie Inc.
7.2. Amgen Inc.
7.3. AstraZeneca plc
7.4. Bayer AG
7.5. Boehringer Ingelheim GmbH
7.6. Bristol-Myers Squibb Co.
7.7. Cipla Ltd.
7.8. Clovis Oncology, Inc.
7.9. Eli Lilly and Co.
7.10. F. Hoffmann-La Roche AG
7.11. GlaxoSmithKline plc
7.12. Kura Oncology, Inc.
7.13. Lupin Ltd.
7.14. Merck & Co., Inc.
7.15. Novartis International AG
7.16. Pfizer Inc.
7.17. PharmaCyte Biotech, Inc.
7.18. Sun Pharmaceutical Industries Ltd.
7.19. Teva Pharmaceutical Industries Ltd.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co.
  • Cipla Ltd.
  • Clovis Oncology, Inc.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Kura Oncology, Inc.
  • Lupin Ltd.
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer Inc.
  • PharmaCyte Biotech, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.